Sinergium's Gateway To Latin American Vaccine & Biologics Markets
With the Latin American vaccines market forecast to more than quadruple in size from just over $150m to 2015 to just under $700m in 2020, opportunities abound for both homegrown businesses and multinationals looking to tap into local markets.
You may also be interested in...
Following the Zika outbreak in Latin America in late 2015, a number of pharmaceutical companies have stepped up their vaccine research efforts against a virus that has now been scientifically determined as the cause of microcephaly and other severe brain defects in babies. But will a product be able to reach the market soon enough to have an impact on the current outbreak?
High inflation, a drop in the price of its commodities and restrictions on imports have not made for a good economic environment in Argentina and have proved a turnoff for investors. But a general election is around the corner and there are hopes that a new administration may set things right. So with change blowing in the wind, companies with flagging pipelines should consider what Argentina has to offer, not least a rich R&D community that helped create the world's first ever cancer vaccine against non-small cell lung cancer, and a vibrant local industry open to partnerships .
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.